| REVIEW ARTICLE |
|
| Year : 2014 | Volume
: 8
| Issue : 3 | Page : 388-391 |
|
|
Remimazolam: The future of its sedative potential
Basavana Gouda Goudra1, Preet Mohinder Singh2
1 Department of Clinical Anesthesiology and Critical Care, Perelman School of Medicine, 680 Dulles Building, 3400 Spruce Street, Philadelphia, United States
2 Department of Anesthesiology and Critical Care medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Sector 12, Chandigarh, India
Correspondence Address:
Dr. Basavana Gouda Goudra
Assistant Professor of Clinical Anesthesiology and Critical Care, Perelman School of Medicine, 680 Dulles Building, 3400 Spruce Street, Philadelphia, PA 19104
United States
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1658-354X.136627
|
|
|
Remimazolam (CNS 7056) is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. It acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil. It is likely to be the sedative of the future, as preliminary phase II trials have shown minimal residual effects on prolonged infusions. It has potential to be used as a sedative in ICU and as a novel agent for procedural sedation. Unlike most rapidly acting intravenous sedatives available presently, the propensity to cause apnea is very low. Availability of a specific antagonist (flumazenil) adds to its safety even in cases of overdose. The present review discusses remimazolam's potential as a new drug in anesthesia along with the presently available literary evidence. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
